Muhammad Wasif Saif, Minsig Choi, Richard Kim
FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely used for the first-line treatmentfor patients with advanced pancreatic adenocarcinoma. Nab-paclitaxel and gemcitabine has replaced the use of many singleagent gemcitabine in these patients population. In patients who progress on the first line therapy use of either 5-FU,leucovorin and oxaliplatin (FOLFOX) or gemcitabine and nab-paclitaxel combination has become a de facto standarddepending on the chemotherapy they received in first line. Progress made in first line chemotherapy has lead to moreinterest in refractory pancreatic cancer. This article examines the 2014 American Society of Clinical Oncology (ASCO)Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, asthese were presented in Abstracts #296, #297, #337, #344, and #381 of the meeting.
